Non-Current Liabilities
Total Liabilities
Alnylam Pharmaceuticals Total Liabilities decreased by 2.9% to $4.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.1%, from $4.10B to $4.05B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 11.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
Detailed definition
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Peer comparison
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
Metric ID:
total_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.66B | $2.72B | $3.06B | $3.03B | $3.15B | $3.60B | $3.70B | $3.65B | $3.81B | $4.00B | $4.05B | $4.04B | $4.01B | $4.17B | $4.17B | $4.10B | $4.32B | $4.62B | $4.18B | $4.05B |
| QoQ Change | — | +2.3% | +12.5% | -0.7% | +4.0% | +14.2% | +2.8% | -1.4% | +4.4% | +5.1% | +1.1% | -0.2% | -0.8% | +4.0% | +0.0% | -1.8% | +5.3% | +7.0% | -9.5% | -2.9% |
| YoY Change | — | — | — | — | +18.8% | +32.6% | +21.3% | +20.4% | +20.8% | +11.2% | +9.3% | +10.7% | +5.3% | +4.2% | +3.0% | +1.4% | +7.5% | +10.7% | +0.1% | -1.1% |
Range$2.66B – $4.62B
CAGR+9.3%
Avg YoY Growth+11.0%
Median YoY Growth+10.0%
Current Streak2 quarters decline
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total liabilities?
- Alnylam Pharmaceuticals (ALNY) reported total liabilities of $4.05B in Q1 2026.
- How has Alnylam Pharmaceuticals's total liabilities changed year-over-year?
- Alnylam Pharmaceuticals's total liabilities decreased by 1.1% year-over-year, from $4.10B to $4.05B.
- What is the long-term trend for Alnylam Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total liabilities has grown at a 11.8% compound annual growth rate (CAGR), from $2.39B to $4.18B.
- What does total liabilities mean?
- The total amount of money the company owes to everyone, both now and in the future.